ERNA-101 — IND submission
2026
We expect to complete the Investigational New Drug ("IND") enabling studies and IND submission in 2026 and to subsequently enter a Phase I investigator sponsored clinical trial in the second half of 2026.Source filing
ERNA biotech catalysts & pipeline
ERNEXA THERAPEUTICS INC · Data as of 2026-10-25